European governments moved on Tuesday to set new curbs in motion to try to rein in a fast-growing surge of coronavirus infections and provide economic balm to help businesses survive the pandemic.
World leaders face an increasingly difficult task holding the disease at bay while keeping their economies afloat as they pin their hopes on as-yet unproven vaccines.
"We are dealing with exponential growth," German Economy Minister Peter Altmaier told a virtual German-French economic conference in Berlin. "In Germany the number of new infections is rising by 70-75% compared to the week before."
The United States, Russia, France, Sweden, Poland and other countries have registered record numbers of infections in recent days as autumn turns to winter in the Northern Hemisphere and people socialize indoors where the risk of infection is higher.
More than 43.4 million people have been infected by the coronavirus globally and 1,158,056 have died, according to a Reuters tally, with the United States leading the way in the number of infections and deaths.
Hundreds of protesters took to the streets across Italy on Monday to vent their anger at the latest round of restrictions, including early closing for bars and restaurants, with demonstrations in some cities turning violent.
In the financial capital Milan, youths hurled petrol bombs at police, who responded with volleys of tear gas. In nearby Turin, luxury shops had their windows smashed and some were ransacked, leading to the arrest of 10 rioters.
Prime Minister Giuseppe Conte was expected to approve measures to help companies hit by the new curbs introduced at the weekend after daily infections increased eight-fold in less than a month.
In France, Interior Minister Gerald Darmanin warned the country to prepare for "difficult decisions" after some of the strictest restrictions currently in place anywhere in Europe have failed to halt the spread of the disease.
The Czech government will ask lawmakers to extend its emergency powers until Dec. 3, Prime Minister Andrej Babis said on Tuesday, as it tries to stem one of the strongest surges in infections in Europe.
There have been at least 8.54 million reported infections and 251,000 deaths caused by coronavirus in Europe so far, according to latest Reuters data. The continent registered a record 230,892 new cases on Oct. 26, up from 67,739 on Oct. 1.
Authorities in Russia, which with 1.55 million infections has the world's fourth largest COVID-19 case load, ordered people to wear facemasks in some public places and asked regional authorities to consider shutting bars and restaurants overnight.
New infections in Belgium, among the hardest-hit countries in Europe, hit a high of more than 18,000 on Oct. 20, almost a 10-fold increase from the high of a spring wave of the pandemic.
The country is expected to decide by this weekend whether a return to a nationwide lockdown is required.
Even Germany, widely praised for its initial response to the pandemic, signaled concern on Tuesday over rising infections, with Altmaier saying the country was likely to reach 20,000 cases a day by the end of this week.
A gauge of global stock markets fell and the U.S. dollar slipped on Tuesday as investors grappled with a surge in coronavirus cases and uncertainty over the impending U.S. election.
Adding to the gloomy sentiment, a new study by Imperial College London found that antibodies against the new coronavirus declined rapidly in the British population during summer, suggesting protection after infection may not be long-lasting. Recovering patients may also suffer a decline in brain function, researchers warned.
In the United States, the number of hospitalized COVID-19 patients is at a two-month high, straining health care systems in some states. The U.S. death toll leads the world at more than 225,300.
"Until November 4th., Fake News Media is going full on Covid, Covid, Covid," President Donald Trump, facing a tough re-election battle on Nov. 3, tweeted on Tuesday. "We are rounding the turn. 99.9%."
Trump has often promoted vaccines as the answer, but none has yet won international approval. Russia in August became the first country to grant regulatory approval for a vaccine after less than two months of human testing, raising eyebrows among skeptical scientists in the West.
Among the candidates, Novavax Inc on Tuesday delayed the start of a late-stage U.S. trial by roughly a month to the end of November, citing delays in scaling up the manufacturing process.
Pfizer Inc said it was not ready to release data from the late-stage trial of the vaccine it is developing with Germany's BioNTech SE.
A vaccine being developed by the University of Oxford and AstraZeneca Plc produces an immune response in both old and young adults, the company said on Monday, raising hopes of a path out of the gloom. (Reuters)